It was reported in an article (marotta, g., roothans, j., astrom, m., musacchio, t., lopiano, l., lanotte, m., lehrke, r., buck, a.K., volkmann, j., isaias, i.U.Brain: a journal of neurology.2016.Doi:10.1093/brain/aww223) that one st.Jude patient with bilateral deep brain stimulation (dbs) of the subthalamic area for treatment of essential tremor (et) experienced secondary dbs failure characterized mainly by chronic-progressive gait ataxia.After an initial benefit on tremor without any side effect, these patients showed a progressive decline in dbs efficacy, beginning >3 months after initial programming.The patients needed repeated stimulation adjustments to compensate for the reduced tremor control.Subsequently, they developed a chronic-progressive gait ataxia, in absence of any other dbs-related adverse event, over a period of at least four weeks of chronic stimulation with unchanged settings.(b)(4).This report reflects information received by fda in the form of a notification per 803.22 (b)(2).
|